Seminars in Oncology
Volume 33, Issue 1 , Pages 139-143, February 2006

Extravasation of Chemotherapeutic Agents: Prevention and Treatment

  • Tiffany V. Goolsby
  • ,
  • Fredric A. Lombardo

      Affiliations

    • Corresponding Author InformationAddress correspondence to Fredric A. Lombardo, MS, PharmD, College of Pharmacy, Nursing, Allied Health Sciences, Division of Clinical and Administrative Pharmacy Sciences, 2300 4th St NW, Washington, DC 20059

Division of Clinical and Administrative Pharmacy Sciences, Howard University College of Pharmacy, Washington, DC

Most chemotherapeutic agents can cause varying degrees of local tissue injuries when extravasated. The medical treatment of extravasation is based on proper maintenance of the intravenous (IV) line and application of cold or warm compresses, plus the use of antidotes when available. Antidotes for extravasation that have been shown to be useful are sodium thiosulfate for nitrogen mustard, dimethylsulfoxide for anthracyclines and mitomycin, and hyaluronidase for the vinca alkaloids. New treatments include dexrazoxane, sargramostim, and hyperbaric oxygen for doxorubicin extravasations. Tissue damage secondary to drug infiltration occurs as a result of one of two major mechanisms: (1) the drug is absorbed by local cells in the tissue and binds to critical structures (eg, DNA, microtubules), causing cell death; and (2) the drug does not bind to cellular DNA. Damage to immediately adjacent tissue is more readily neutralized than is damage to surrounding tissue.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(05)00437-9

doi:10.1053/j.seminoncol.2005.11.007

Seminars in Oncology
Volume 33, Issue 1 , Pages 139-143, February 2006